Skip to main content
. Author manuscript; available in PMC: 2019 Aug 1.
Published in final edited form as: Surgery. 2018 May 3;164(2):262–273. doi: 10.1016/j.surg.2018.03.008

Fig 5. GDF11 treatment activated kidney pSMAD2 and was blocked by co-administration of Follistatin.

Fig 5

(A) Immunohistochemistry of pSMAD2 in kidney sections of outer cortex from control and GDF11-treated mice at 12 d. (B) Western blots of SMAD2 and pSMAD2 on kidney extracts from control or GDF11-treated mice at the indicated day (d) after injection. (C) Survival of mice dual-injected in opposite legs with CHO-control/CHO-follistatin cells (n = 6), CHO-control/CHO-GDF11 (n = 6), or CHO-follistatin/CHO-GDF11 cells (n = 5). In this trial, CHO-GDF11 mice were euthanized when they became moribund 9d after injection. CHO-control/CHO-follistatin-treated mice were euthanized due to tumor burden at 18d. Mice bearing both CHO-follistatin/CHO-GDF11 cells survived to 18 d and were euthanized. P < 0.0001